Clinical trials: Vaccine Response
Rabies
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis.
- Trial name
- MALRAB (NCT02564471)
- Testing
- Chloroquine, Atovaquone and Proguanil, Doxycycline
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Sepsis
Effects of BCG on Immune Response
In the present study, we want to investigate whether BCG-vaccination enhances the innate immune response in humans in vivo during (single) human endotoxemia.
- Trial name
- NCT02085590
- Testing
- BCG vaccine, Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03022435
- Testing
- TIV, High-Dose TIV, LAIV
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Stanford University
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
HIV Infections
Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
The purpose of this study is to determine the safety of and immune response to an investigational HIV vaccine, VRC-HIVADV014-00-VP, with or without a second investigational HIV vaccine, VRC-HIVDNA016-00-VP, in HIV uninfected…
- Trial name
- NCT00124007
- Testing
- VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP
- Where
- 3 sites in Kenya, Rwanda
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Infants, Mothers
Improving Rotavirus Vaccine Immune Response
Rotavirus is the leading cause of severe gastroenteritis in infants and young children worldwide and is estimated to account for 600,000 deaths in children <5 years of age. However, live oral enteric vaccines (e.g.
- Trial name
- NCT01825109
- Testing
- Rotavirus Vaccine & Breastfeeding
- Where
- Bangladesh
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Influenza Virus Vaccine Adverse Reaction, Influenza Vaccine Allergy
Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes
Seasonal influenza vaccination was used to assess whether induction of immunity as well as the rate of side effects is influenced by the timing of the last training session before vaccination.
- Trial name
- NCT03654937
- Testing
- Influenza Vaccination
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Universität des Saarlandes
COVID-19 Pandemic, D Vitamin Deficiency
Impact of Vitamin D Supplementation on COVID-19 Vaccine Response and IgG Antibodies in Deficient Women.
Decreased immunity in individuals causes a decrease in vaccine response, and vitamin D worsens this course. Vitamin D is thought to be a vitamin that can strengthen the innate immune response, inhibit the adaptive system, and…
- Conditions
- COVID-19 Pandemic, D Vitamin Deficiency, Antibody Hypersensitivity
- Trial name
- CoVıD-19 (NCT05447065)
- Testing
- Vitamin D supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Ege University
Pertussis, Pregnancy Related
Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women
This study evaluated the seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in…
- Trial name
- NCT03498300
- Testing
- Tdap vaccine
- Where
- Thailand
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Influenza, Virus Diseases
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
In the 20th century, influenza pandemics occurred in 1918, 1957, and 1968, and were associated with significant morbidity and mortality.
- Trial name
- NCT00734175
- Testing
- H6N1 Teal HK 97/AA ca recombinant vaccine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
The purpose of this study is to assess the seropersistence of TBE antibodies in children and adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34 months after completion of primary immunization…
- Trial name
- NCT00161967
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Pfizer
HPV Infection, HPV Vaccination
Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life and duration of protection is critical to vaccine effectiveness in protection from oncogenic hrHPV infection.
- Trial name
- NCT05435209
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- Kenya
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- University of Washington
Influenza, Hepatitis A
Effects of Aging on Primary and Secondary Vaccine Responses
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (>65 years) subjects whose yearly influenza vaccine responses have been studied extensively…
- Conditions
- Influenza, Hepatitis A, Typhoid, Healthy Adults
- Trial name
- SLVP033 (NCT03312699)
- Testing
- Fluzone® quadrivalent, Fluzone High Dose, Fluad
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Stanford University
Immune Response
Immune Responses Induced by Different Licensed Influenza Vaccines
The goal of this research is to find out how the body's immune system responds to different manufacturer's "flu" vaccines.
- Trial name
- NCT00902278
- Testing
- Flulaval, Fluvirin, Fluzone
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Malaria
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
Background: People bitten by mosquitoes carrying weakened malaria parasites could fight off the disease if later exposed to normal malaria parasites.
- Trial name
- NCT02015091
- Testing
- PfSPZ Vaccine
- Where
- 2 sites in United States
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Cancer Prevention
Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vaccination
This is a single-center, prospective, open-label, partially randomized, matched-controlled trial designed as a cohort study. The study plans to enroll 360 healthy female participants aged 18 to 45 years, divided into three…
- Trial name
- NCT07530679
- Testing
- 9-valent HPV vaccination at months 0 and 6, 9-valent HPV vaccination at months 0 , 1 and 6
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
HIV Infections
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
The purpose of this study is to test the safety of an HIV DNA vaccine (EP HIV-1090) and to test whether or not the vaccine can stimulate immune system responses in HIV uninfected people.
- Trial name
- NCT00054860
- Testing
- EP HIV-1090
- Where
- 5 sites in United States, Botswana
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune System Diseases
Zoster Vaccine Response in the Frail Elderly
This study is being done to evaluate the zoster vaccine response in the nursing home elderly (80 years or older). As the immune system ages, the response to vaccines is not always as strong as in younger people.
- Trial name
- NCT01328548
- Testing
- Zostavax
- Where
- Canada
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- McMaster University
Meningococcal Disease, Meningococcal Meningitis
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescent subjects who completed study V59P6 in which they received either Novartis Meningococcal (MenACWY) Conjugate Vaccine or Licensed…
- Trial name
- NCT01018732
- Testing
- Novartis Meningococcal (MenACWY-CRM) vaccine
- Where
- 3 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.
- Trial name
- NCT01139021
- Testing
- rMenB+OMV NZ
- Where
- 19 sites in Czechia, Finland
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines